Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

AIDS. 2022 Nov 15;36(14):2077-2079. doi: 10.1097/QAD.0000000000003350. Epub 2022 Sep 15.

Abstract

Dolutegravir 50 mg is registered for use in children weighing 20-40 kg. This approval is based on data from an African paediatric cohort, and no pharmacokinetic data was available from children outside of Africa. This study provides further evidence of the effective use of dolutegravir 50 mg in children weighing 20 to 40 kg by showing that concentration data gathered in clinical practice shows adequate concentration levels in Dutch children without a safety signal.

MeSH terms

  • Africa South of the Sahara
  • Child
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / pharmacokinetics
  • Humans
  • Oxazines
  • Pyridones

Substances

  • dolutegravir
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Pyridones